Vericel Corp Reports Preliminary 2025 Financial Results and Business Updates
Vericel Corp (NASDAQ: VC) announced preliminary financial results for 2025 and key business updates on January 13, 2026. The company projects total revenue of $276 million for 2025, driven largely by its flagship product, MACI.
Revenue Highlights
| Metric | 2025 Projection |
|---|---|
| Total Revenue | $276 million |
| MACI Revenue | $239.5 million |
| Q4 Total Revenue | $239.5 million |
| Q4 MACI Revenue Growth | 23 % |
The 23 % growth in MACI revenue in the fourth quarter reflects an expansion in treatment indications and increased patient enrollment in ongoing clinical programs.
Business Updates
- Product Portfolio: Vericel’s proprietary Tissue Repair Cell (TRC) adult stem cell platform continues to underpin the development of autologous stem/progenitor cell products for tissue repair and regeneration.
- Clinical Pipeline: No specific clinical milestones were disclosed in the preliminary update; however, the company remains focused on advancing its regenerative medicine applications.
- Financial Outlook: The revenue forecast of $276 million places Vericel well within its strategic targets for 2025, supporting ongoing investment in research and development, manufacturing capacity, and regulatory submissions.
Market Context
- Current Trading: As of January 11, 2026, Vericel’s share price closed at $36.59.
- Market Capitalization: $1.95 billion USD.
- Valuation Metrics: The company trades at a price‑to‑earnings ratio of 148.85, reflecting expectations of significant growth in the regenerative medicine sector.
The preliminary financial results confirm Vericel’s trajectory toward substantial revenue growth in 2025, driven by the MACI product line and supported by its advanced stem cell technology platform.
